Sigma shares jump 7% on results and Chemist Warehouse expansion

Female pharmacist smiles with a digital tablet.

Sigma Healthcare Ltd (ASX: SIG) shares are having a strong start to the day.

In morning trade, the Chemist Warehouse owner’s shares are up 7% to $3.20.

This follows the release of another strong half-year result from the retail pharmacy franchisor and pharmaceutical wholesaler and distributor.

Sigma shares jump on results day

For the six months ended 31 December, Sigma delivered strong financial performance, continued expansion of the Chemist Warehouse (CW) branded network in both domestic and international markets, and solid progress on its integration and synergy delivery.

The company posted a 14.9% increase in revenue to $5.5 billion, with CW branded store sales in Australia growing 17.2% to reach $5.1 billion. Management notes that it benefitted from an expanding network and strong customer engagement.

Like-for-like sales across the CW branded store network were up 15%, which management believes demonstrates a pharmacy model and value proposition that continues to resonate with customers.

In addition, it notes that total sales also benefited from the structural uplift from the sale of GLP-1 class of medicines like Ozempic and Mounjaro and the strategic decision to distribute online orders directly from stores.

Thanks to a combination of operating leverage, synergy benefits, and product mix, Sigma recorded a 34 basis points increase in its normalised EBIT margin.

This ultimately led to the company posting a 19.2% increase in normalised net profit after tax to $392 million.

In light of this, a 2 cents per share fully franked interim dividend was declared.

Management commentary

The company’s CEO and managing director, Vikesh Ramsunder, was pleased with the half. He said:

Our first half performance reinforces the strength of Sigma. As an integrated healthcare business we see long-term opportunities for growth, headlined by sustained performance across our core domestic market, led by CW branded stores. This has continued to be a consistent feature of the CW business over the past two decades.

CW branded store sales in Australia grew 17.2% for the half to reach $5.1 billion, benefiting from an expanding network and strong customer engagement. LFL sales across the CW branded store network were up 15.0%, demonstrating a pharmacy model and value proposition that continues to resonate with customers. Total sales also benefited from the structural uplift delivered from the sale of GLP-1 class of medicines and the strategic decision to distribute online orders directly from stores.

Outlook

Sigma has started the second half positively. It revealed that year to date trading, including the first seven weeks of the second half, has seen growth momentum continue.

During this period, Australian CW branded store sales are up 16.6% and like for like sales are up 14.4%. Growth in its international retail network continues.

The post Sigma shares jump 7% on results and Chemist Warehouse expansion appeared first on The Motley Fool Australia.

Should you invest $1,000 in Sigma Healthcare right now?

Before you buy Sigma Healthcare shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Sigma Healthcare wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys…

* Returns as of 20 Feb 2026

.custom-cta-button p {
margin-bottom: 0 !important;
}

More reading

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.